HOLLISTON, Mass. -- (BUSINESS WIRE) -- Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at the 2nd Annual Regen Med Investor Day in New York City on March 26, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
The presentation will be at 1:30 PM ET at the Metropolitan Club, located at 1 East 60th Street in Manhattan. A live video webcast of Mr. Green’s presentation will be available at www.arminvestorday.com/webcast/ and will also be archived at that same link shortly after the conference.
About Regen Med Investor Day
Regen Med Investor Day (http://alliancerm.org/event/regen-med-investor-day) is the only financing event organized specifically for the regenerative medicine sector, providing institutional, strategic and venture investors a unique opportunity to gain insight into the top regenerative medicine and advanced therapies companies. The one-day, high-impact program provides institutional investors and life science analysts with insight from the industry’s leading small- and mid-cap companies. Through dynamic discussions between key opinion leaders, top analysts and senior executives, attendees have exclusive access to the sector’s leading stakeholders and hear the latest on the industry’s prominent disease indications. Additionally, the field's most promising companies, both public and private, from across the globe give focused presentations. By bringing together the leaders in regenerative medicine with top financial experts and investors, this meeting provides a unique and distinguished forum to explore the latest investment trends and opportunities within this budding sector.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreathTM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.